مباشر

FierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test Endpoints NewsAntifungal from F2G, Shionogi succeeds in Phase 3 study BioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haul Endpoints NewsKardigan raises $400M in IPO to back three clinical-stage cardio drugs Endpoints NewsBiogen makes up to $1B deal for secretive anti-inflammatory biotech FierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game SchunkHealthy and thriving: ARPM, MAPP companies maintain safety as top priority - Rubber News 10x Genomics Blog10x Genomics (TXG) Partners with Cleveland Clinic for Bladder Ca - GuruFocus Clinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?AgilentAgilent (A) Has a Consumables-and-Service Analytical Platform Bigger Than a Biotech-Funding Proxy - AlphaStreet Clinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting Microglia Endpoints NewsFDA gives rejected drugs another chance in post-Makary era

BioPharma Dive ١٨ يونيو ٢٠٢٦

Kardigan extends biotech’s streak of big IPOs with $400M haul

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year s...

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.